ALLO
Allogene Therapeutics, Inc. Common Stock
US Stock$15.29
Open: $15.5 High: $16.075 Low: $15.37 Close: $15.98
Range: 2022-08-08 - 2022-08-09
Volume:576,003Market: Open
Powered by Finage Stock APIDelayed data
ALLO
Allogene Therapeutics, Inc. Common Stock 210 EAST GRAND AVENUE https://www.allogene.com
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.- CEO:
- Employees: 334
- Sector:
- Industry:
ALLO News
Latest news about the ALLO
Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land' by Reuters at 10/15/21, 8:45 AMView More →- U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies by Reuters at 5/7/20, 10:06 PMView More →